CJC-1295
CJC-1295 (without DAC, chemically equivalent to Modified GRF 1-29) is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH), engineered with amino-acid substitutions that resist enzymatic degradation and stimulate the pituitary to release growth hormone.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
CJC-1295 binds and activates the GHRH receptor (a Gs protein-coupled receptor) on anterior pituitary somatotroph cells, triggering adenylate cyclase activity, a rise in intracellular cAMP, and PKA-mediated stimulation of growth hormone synthesis and pulsatile secretion. Compared with native GHRH(1-29) or sermorelin, several amino acid substitutions (relative to the endogenous sequence) reduce its susceptibility to enzymatic cleavage, extending its functional half-life from minutes to roughly half an hour. Unlike the DAC-conjugated version, it does not bind serum albumin, so it preserves a more pulsatile, GHRH-like pattern of GH release rather than continuous elevation.
Typical results seen in research
Because this non-albumin-bound form shares its core sequence and receptor pharmacology with GHRH(1-29)/sermorelin, it is expected to produce transient, dose-dependent increases in GH and downstream IGF-1 similar to other short-acting GHRH agonists; however, dedicated published human pharmacodynamic or efficacy trials specifically on the 'no-DAC' formulation (as distinct from the long-acting DAC-conjugated molecule used in the pivotal human study) are lacking. Most of the peer-reviewed human data reported under the 'CJC-1295' name actually describes the long-acting DAC-conjugated compound, so claims about this specific short-acting form rely on inference from GHRH receptor pharmacology rather than direct trial data.
How it’s commonly used
In research settings, CJC-1295 (no DAC) is administered by subcutaneous injection, typically on a more frequent schedule than the DAC-conjugated form because of its shorter duration of action. It is studied primarily in the context of growth hormone axis and GHRH receptor research rather than for any approved clinical indication.
- Proceedings of the National Academy of Sciences · 1984 Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor
- Journal of Clinical Endocrinology & Metabolism · 2006 Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- American Journal of Physiology-Endocrinology and Metabolism · 2006 Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.